Innovation

The race to develop treatments and a vaccine for COVID-19 highlights the value of repurposing solutions.

MIT SMR editor in chief Paul Michelman kicks off the Disruption 2020 Virtual event.

There are four common misconceptions that leaders often succumb to when thinking about disruptive innovation.

Even before the COVID-19 pandemic, traditional education models were poised to be disrupted.

Tucker Marion and Sebastian Fixson outline four essential skills workers need to master to succeed in digital environments.

To ensure success, entrepreneurs need to create two business plans: one for disruption and one for cooperation.

Amy Webb outlines the 11 sources of change that could disrupt your organization.

SAP’s Max Wessel explains why advisory board guidance is critical in innovation.

The current pandemic presents an opportunity for creativity to rethink skills development, worker protections, and health care.

Western organizations shouldn’t attempt to transplant what works in their own countries into developing economies, but instead should become familiar with the environments there and seize existing opportunities in-context.

To launch successful products that delight customers, companies need a new approach to data analytics.

How to boost innovation capacity and institutional pride, and addressing tech inequity and the ethics of automation.

Companies must think critically about how to address the issue of technology access and inequity throughout the COVID-19 crisis.

External innovation is a way to broaden your portfolio, not a substitute for internal innovation.

CEOs who manage crises using intuition, logic, and emotion are the best role models.

The world’s unbanked populations represent a compelling social need and a tremendous economic opportunity.

Swarm systems draw input from individuals and use algorithms to optimize system performance in real time.

Adjusting business strategies and plotting comebacks in the face of uncertainty.

Amid pandemic-driven market changes, opportunities await organizations that proactively adjust their business strategies.

Pharma’s existing model may be a liability in the race to develop drugs and vaccines to combat COVID-19.